Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2.6
Needham analyst Mike Matson maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $3.1 to $2.6.
Analysts Downgrade Rating On Qualtrics Post Takeover Deal; View Competing Bid At Higher Price Unlikely
Raymond James analyst Brian Peterson downgrades Qualtrics International Inc (NASDAQ:XM) from Outperform to Market Perform. Silver Lake and CPP Investment agreed to…
Analyst Ratings for Wintrust Finl
Over the past 3 months, 4 analysts have published their opinion on Wintrust Finl (NASDAQ:WTFC) stock. These analysts…
Analyst Expectations for Amylyx Pharma’s Future
Over the past 3 months, 5 analysts have published their opinion on Amylyx Pharma (NASDAQ:AMLX) stock. These analysts…
Citigroup Maintains Neutral Rating for Visteon: Here’s What You Need To Know
Citigroup has decided to maintain its Neutral rating of Visteon (NASDAQ:VC) and raise its price target from $145.00…
JP Morgan Downgrades Crestwood Equity Partners: Here’s What You Need To Know
JP Morgan downgraded its rating of Crestwood Equity Partners (NYSE:CEQP) to Neutral with a price target of $28.00,…
‘Cinderella Story Over,’ Says Analyst: 6 Potential Tech Losers From SVB’s Dark Crash
Calling SVB Financial Group’s (NASDAQ: SIVB) Silicon Valley Bank the “Godfather of the Silicon Valley,” Wedbush analyst Daniel Ives weighed in on the impact of it
Wells Fargo Downgrades Momentive Glb to Equal-Weight, Lowers Price Target to $9.46
Wells Fargo analyst Brian Fitzgerald downgrades Momentive Glb (NASDAQ:MNTV) from Overweight to Equal-Weight and lowers the price target from $10 to $9.46.